Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tissue-engineered bone tumor as a reproducible human in vitro model for studies of anti-cancer drugs

ABSTRACT: Tissue-engineered bone tumor as a reproducible human in vitro model for studies of anti-cancer drugs

PROVIDER: PRJNA558389 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Tissue-engineered bone tumor as a reproducible human in vitro model for studies of anti-cancer drugs

Project description:We investigated changes in bone and Ewing’s Sarcoma transcriptomes among control and treated cells grown in 2D plates, or within engineered bone scaffolds.

2020-01-15 | GSE135323 | GEO

Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.

Project description: Not available

| S-EPMC8204946 | biostudies-literature

Expression data from anti-mycoplasma drugs treated gastric cancer cells

Project description:Various anti-mycoplasma drugs have different effects on cells growth We used microarrays to detail the global programme of gene expression underlying gastric cancer cells treated with anti-mycoplasma drugs and identified distinct classes of up-regulated genes during this process.

2015-10-08 | GSE73777 | GEO

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Project description:This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.

| 2298670 | ecrin-mdr-crc

Chemical profiling of the genome with anti-cancer drugs defines target specificities

Project description:Many anti-cancer drugs induce DNA breaks to eliminate tumor cells. The anthracycline topoisomerase II inhibitors can also evict histones. We performed a genome-wide high-resolution mapping of chemotherapeutic effects of various topoisomerase I and II inhibitors. We show that different drugs target different types of chromatin for induction of DNA damage and histone eviction. Topoisomerase inhibitors topotecan and etoposide similarly target transcriptionally active chromatin for DNA damage. Daunorubicin induces DNA breaks and evicts histones in active chromatin, thus quenching local DNA damage response. The analog aclarubicin evicts histones in H3K27me3-marked heterochromatin. These results can guide rational treatment decisions regarding these genome manipulating anti-cancer drugs. FAIRE-seq and g-H2AX ChIP-seq were performed on K562 cells after drug exposure

2015-05-10 | E-GEOD-60395 | biostudies-arrayexpress

LNCAP in-vitro treatment with androgen receptor targeting drugs

Project description:Gene expression in LNCaP cells after treatment with the androgen receptor targeting drugs bicalutamide (BIC), enzalutamide (ENZ) and apalutamide (ARN) in the presence or absence of dihydrotestosterone (DHT).

2022-09-07 | GSE211781 | GEO

Hypoxia impedes vasculogenesis of in vitro engineered bone.

Project description: Not available

| S-EPMC3246420 | biostudies-literature

Human in vitro vascularized micro-organ and micro-tumor models are reproducible organ-on-a-chip platforms for studies of anticancer drugs.

Project description: Not available

| S-EPMC7606810 | biostudies-literature

Anti-cancer drugs curaxins target the 3D genome organization

Project description:Anti-cancer drugs curaxins target the 3D genome organization

| PRJNA505307 | ENA

The effect of anthelmintic drugs on human leukocyte gene expression in vitro

Project description:Ivermectin and Diethylcarbamizine (DEC) are used in the elimination programs for lymphatic filariasis and onchocerciasis. It has been proposed that the drugs may have an effect on the host immune system that aids in parasite killing/elimination. We tested this directly by exposing human neutrophils and monocytes to the drugs in vitro.

2019-02-06 | GSE126091 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data